www.starpharma.com
Starpharma is a world leader in the development of dendrimer nanotechnology for pharmaceutical, life-science and other applications. The lead pharmaceutical development product is VivaGel®, a vaginal microbicide designed to prevent the transmission of HIV and genital herpes. Starpharma is developing a VivaGel®-coated condom under a licence agreement with SSL International plc (LSE:SSL), manufacturer of Durex®, the market-leading condom brand worldwide. Products based on Starpharma’s technology are on the market as diagnostic elements and laboratory reagents through licence arrangements with partners including Siemens and Merck KgA. Starpharma is exploring dendrimer opportunities in materials science applications including water remediation and animal health products.
Orbis Investment Management acquires 2.6m shares in Starpharma Holdings
Substantial shareholder Orbis Investment Management has significantly increased its investment in Australian-listed biotechnology company, Starpharma Holdings (ASX:SPL, OTCQX:SPHRY) with the acquisition of 2,564,237 SPL shares on-market at an average price of $0.64 per share between 21 May to 16 June.
Orbis lodged the change in interests of substantial holder and now owns 20,809,309 shares or 8.71% of Starpharma.
Starpharma is a market leader in the development of dendrimer products for pharmaceutical, life-science and other applications.
Its partnerships include Durex, Lilly, Elanco, Stiefel (now GSK), Siemens and Merck. Commencement of royalty revenue is estimated to commence in CY11 with VivaGel coated condoms.




















